MHRA (UK) approves Jemperli (dostarlimab), a treatment for some types of endometrial cancer in adults – GSK

The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised a new indication for Jemperli (dostarlimab), a treatment for some types of endometrial cancer in adults. It can be used to treat patients that have a tumour abnormality called mismatch repair deficient (dMMR) / microsatellite instability-high (MSI-H) when the cancer is at an advanced stage when first diagnosed or has returned after previous treatment. Endometrial cancer is a cancer of the womb (uterus) lining and can occur in any person with a womb, although it’s most common in those who have been through the menopause.

Jemperli is now authorised to be used together with chemotherapy to slow the progression of these cancers, increasing life expectancy for patients. This is the first medicine licensed as first line treatment for primary advanced or recurrent endometrial cancer.